key: cord-0792409-2kmmogfm
authors: Casadei, Barbara
title: Barbara Casadei opening at virtual ESC Annual Congress 2020: Outgoing ESC President Barbara Casadei speaks of the lessons learnt during the COVID-19 pandemic at this first-ever virtual Congress
date: 2020-08-29
journal: Eur Heart J
DOI: 10.1093/eurheartj/ehaa681
sha: 52e6bcd9a0eb32dac70c009bd23fdb44c22a1006
doc_id: 792409
cord_uid: 2kmmogfm

nan

None of us would have imagined after Paris that we would meet virtually this year. And this is a relatively small change and one of many we have had to adapt to. We have lived and worked in ways most of us had not experienced before. And, in the same way, that we are periodically challenged by natural catastrophes, we have had our welloiled, highly sophisticated systems and our way of living, shaken by a single strand of RNA. Over the last 10 months, because of the coronavirus pandemic, we have been moving backwards and we have been moving forward.

As highly skilled professionals with an evidence-based armamentarium that is second to none, we are accustomed to knowing what to do and to doing it well. But patient care in the COVID-19 outbreak has not been 21st-century medicine-it was not what we trained for-nor was it what our trainees were aspiring to do.

We have used this drug and that drug on COVID-19 patients without knowing whether they would bring benefit or harm to them. We have had to base our practice on anecdotes and even our most respected journals have published studies that, either because of their small size or inadequate design, they would not have considered publishing a year ago. All of this has confused matters rather than inform care.

We say, sometimes proudly and sometimes sadly, that our society is a product of globalization. We have also said that COVID-19 is a product of globalization. But what the COVID-19 pandemic has shown is that we are, if anything, not globalized enough. On the contrary, we are still too nation-centred and parochial-yet at times such as these what we have in common counts much more than our differences. With each wave of the COVID-19 outbreak, from China, to Italy, to the UK, and Spain, most countries have (with some exceptions) dramatically failed to see it coming and prepare effectively-delays in instigating social distancing, travel restrictions, and test-and-trace strategies are hard to justify. Did we really think that the SARS-COVID-2 virus would behave differently in the UK than in Italy, or in the USA than in Asia?

And, about going backwards, if we ever needed a reminder of how far we have come in cardiology, the COVID-19 pandemic has really brought it home. Because the unimaginable has happened: fear of infection and in some areas, an overwhelming demand on the ambulance services have meant that patients with acute coronary syndromes (ACS) or stroke have either not sought medical attention or have come to hospital too late to benefit from revascularization.

In China, Europe, and the USA investigators have reported a 50% reduction in ACS admissions during the outbreak. The same reduction has been reported in every continent in a worldwide survey conducted by the European Society of Cardiology (ESC). 1 Different cultures, different health systems, different prevalence of COVID-19 same fear and same response to fear. As a result, we have all had a stark reminder that our ability to open an occluded coronary or cerebral artery and to have a 24-7 service in place that can do this promptly has been a revolution-one that, over the last 30 years, has saved many lives and prevented disability in millions of people. Regrettably, during the COVID-19 outbreak, we have all been reminded of what a heart attack or a stroke used to be in the 1970s. We have seen the complications of untreated myocardial infarctions, we have seen an excess of out-of-hospital cardiac arrest and death, and we will likely see an increase in the incidence of heart failure. Now that we know, let us make sure we learn from this experience and together, prevent this from happening again. Let us plan, invest and prepare so that we can offer assurance to our patients that coming to hospital will be safe during this outbreak and in future health emergencies. We must make sure we continue to save the lives we know how to save.

Crucially, let's also make sure that all data we are collecting on our patients in each of our countries, either in registries or for administrative purposes, can be rapidly accessed and used to plan our response to any emergency as well as to assess how well we care for our patients, and how we can improve further. At present, the best we can aspire to is to use health data to describe what has already happened-useful as that may be, it is not enough. We live in a world where for many years we have at least tried to forecast the weather, we collect data to predict tsunamis, hurricanes, earthquakes and volcano eruptions-but we couldn't monitor the impact of COVID-19 on ACS admissions in real time and thus we couldn't immediately act to prevent unnecessary deaths and disability.

To deal with the unexpected, we must be able to monitor health trends in real-time; it is not sufficient to collect data and store them, we must be able to use them and use them in a timely fashion.

Data also allow us to learn from each other, so that we can effectively tackle any global health threat with global knowledge and locally adapted policies and let us not forget that cardiovascular disease (CVD) is still the No 1 health threat worldwide.

Most importantly, let's look ahead with the confidence that the ingenuity of scientists, the dedication of health professionals, and the muscle of industry will yet again, get us out of this health crisis with renewed confidence and a bag of experience and knowledge that will propel us further in the quest to conquer CVD.

Let us not waste our imagination in rehearsing what can go wrong from now on-our countries, the ESC-your Society-and our patients need health professionals and scientists with innovative ideas, people with imagination and people who have the resilience and the knowhow to find new solutions. It is the ability to see change coming and use it as an opportunity that makes the difference between a professional life of frustration and one of excitement.

And what opportunities have we seen over the last year?

We have again seen the unimaginable-the COVID-19 pandemic has brought urgency and with urgency, we have learnt to cut kilometres of redundant red tape. Irrational bureaucratic barriers to progress have fallen. We have moved forward at speed. We have learnt that because we are used to doing things in a certain way, it does not mean that is the best way. As a result of the outbreak, clinical trials were launched in record time and vaccines are being developed rapidly. 2 We have tested new, more agile study designs. We have used our health systems to support patient recruitment and follow-up. 3 We have all learnt to work with new partners. We have embraced tele-medicine and have bypassed journals to share key information and data as soon as they became available. And we have learnt to work flexibly and effectively, sometimes from home; we have saved commuting time that was not necessary, reduced pollution and have not dragged frail patients to hospital carparks and waiting rooms unnecessarily. Some of us have been brought closer to our family and children, to our colleagues and trainees, and to the emotional needs of our patients and their caregivers.

We have amply demonstrated that we, healthcare professionals, do not need to be micromanaged to give our best. Rather, we need to be valued and inspired. Now we must not forget that the unthinkable is possible. We must not forget what we are capable of achieving. Now we need to take stock of this experience and use it to tackle the world's number one killer-CVD.

Let us put this into perspective. Even the tragic reality of more than half a million deaths due to COVID-19 worldwide in 8 months-and hopefully just once-seems small when compared with 17.9 million deaths due to CVD every year, one-third of which are premature. 4, 5 In addition, we now know that our patients are at high risk of dying of COVID-19 and we know that many patients with acute and chronic CVD decided not to come to hospital because of this, or had their procedures cancelled. 1 We need to find new solutions to the CVD pandemic. If fear of COVID-19 has overcome cultural, geographic, and societal differences with disastrous consequences for patients with CVD-we need to turn that very same common engine, our common frustration against a virus that threatens our values and our community into something positive.

With science as our pilot, we need to look at the future, the future of our mission with new inquisitive eyes. We need to take stock of what we know now to discover new and better ways to prevent and treat CVD. We must not get used to millions of people suffering, millions of people dying every year of CVD, as if it were an inevitability.

As the Spanish flu marked the moment when health became political 6 let's take stock of our recent experience and remind ourselves that health is the thermometer of our progress, the meter against which we measure our level of civilization.

It is particularly at times like these that we are reminded that what we cherish, all of our great achievements, can be easily lost unless we fight for them. So, we must all try our hardest to create an environment for medical progress to thrive and accelerate, to provide the right incentives for ourselves and the younger generations. How appropriate therefore that this year's Congress spotlight should be 'the cutting edge of cardiology'-that rainbow over the horizon, which through the effort and ingenuity of our community, will ensure progress in the care for our patients with CVD and prosperity for our Society.

are available as supplementary material at European Heart Journal online